Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New Elite Feature:   Find Similar Charts in Seconds

Learn How
Market News Market Pulse Stocks News ETF News Crypto News

MaxCyte, Inc

Contributing Author

Recent Articles by MaxCyte, Inc

Sep-23
MaxCyte Appoints Sidharth Kapileshwar as Chief Corporate Development Officer MXCT GlobeNewswire
Sep-11
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MXCT GlobeNewswire
Aug-19
MaxCyte launches CHANGE-seq-BE and ONE-seq-BE to strengthen off-target assessment for genome editing therapies MXCT +9.45% GlobeNewswire
Aug-12
MaxCyte Reports Second Quarter 2026 Financial Results MXCT MXCT +9.45% GlobeNewswire
Jul-21
MaxCyte Announces Multi-Platform Technology License Partnership with Genentech to Advance Cell Therapy Development MXCT +5.13% GlobeNewswire
Jul-15
MaxCyte to Report Second Quarter 2026 Financial Results on August 12, 2026 MXCT GlobeNewswire
May-12
MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance MXCT MXCT +24.06% GlobeNewswire
Apr-29
MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026 MXCT -6.78% MXCT +7.63% GlobeNewswire
Mar-31
MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MXCT MXCT +5.92% GlobeNewswire
Mar-24
MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance MXCT MXCT -6.81% GlobeNewswire
Mar-23
MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer MXCT GlobeNewswire
Feb-24
MaxCyte unveils ExPERT DTx, a 96-well electroporation platform to accelerate discovery MXCT +5.01% GlobeNewswire
Feb-23
MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026 MXCT GlobeNewswire
Jan-12
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results MXCT GlobeNewswire
Nov-12
MaxCyte Announces Planned CFO Transition in 2026 MXCT GlobeNewswire
Nov-12
MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance MXCT GlobeNewswire
Nov-05
MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance MXCT GlobeNewswire
Oct-08
MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025 MXCT +9.68% GlobeNewswire
Oct-06
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors MXCT GlobeNewswire
Sep-22
MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability MXCT MXCT +10.32% GlobeNewswire
Aug-06
MaxCyte Reports Second Quarter 2025 Financial Results and Updates Full Year 2025 Guidance MXCT MXCT -29.90% GlobeNewswire
Aug-04
MaxCyte Signs Platform License Agreement with Adicet Bio MXCT GlobeNewswire
Jul-31
MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy Pipeline MXCT GlobeNewswire
Jul-09
MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025 MXCT GlobeNewswire
Jun-11
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies MXCT GlobeNewswire
May-07
MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance MXCT MXCT -11.31% GlobeNewswire
May-07
MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 Guidance MXCT MXCT -11.31% GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)